Abstract: Improved methods of treatment are provided for patients suffering from cancer. The methods identify whether a tumor will be responsive to treatment with a therapeutic regime that includes anti-Her2 therapeutic agents. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.
Type:
Grant
Filed:
May 31, 2016
Date of Patent:
February 19, 2019
Assignees:
Expression Pathology, Inc., Department of Internal Medicine and Cancer Research, Seoul National University Hospital
Inventors:
Yung-Jue Bang, Todd Hembrough, Eunkyung An, Do-Youn Oh